一分钟看懂
这是一项关于恶性肿瘤的I 期研究，登记的药物或干预包括IL-12 GEMys；Cyclophosphamide；Fludarabine；Cetuximab，当前状态为尚未开始招募。登记地点显示中国Bethesda有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
IL-12 GEMys；Cyclophosphamide；Fludarabine；Cetuximab · I 期
登记条件中文摘要
登记的基本范围为不限性别，年龄18 岁至120 岁；另列出8项专业入选条件，需结合英文原文并由研究团队确认。
登记记录列出8项主要排除条件，具体医学含义需结合英文原文并由研究团队确认。
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- National Institutes of Health Clinical Center · Bethesda
公开的入选条件
- * Relapsed or refractory solid tumor malignancies for whom standard measures do not exist or are no longer effective. Must have histologic confirmation of original diagnosis or relapse.
- * Participants must have evaluable (measurable or not measurable) disease.
- * Part B only: Participants must:
- be willing to undergo mandatory pre- and post-treatment tumor biopsies. Tumor tissue should either be taken from non-target lesions or from target lesions where sampling can be done without impacting lesion measurement
- --have disease amenable to biopsy to allow to perform pre- and post-tumor biopsies.
- * Participants with treated brain metastases are eligible if follow-up brain imaging after central nervous system (CNS)-directed therapy and close monitoring for over 3 months shows no active progression.
- * At least one prior cancer treatment when upfront standard therapy exists. Note: There is no limit to the number or type of prior treatment regimens.
- * The indicated time must have elapsed since any systemic anti-cancer therapy prior to leukapheresis.
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT07672483；登记信息更新于 2026-10-02。